Polymyositis, dermatomyositis and inclusion body myositis Nosological aspects;Polymyosite, dermatomyosite, myosite à inclusions, aspects nosologiques

Presse Medicale

Volumn 32, Issue 35, 2003, Pages 1656-1667

  Eymard, Bruno ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CREATINE KINASE; CYTOKINE; HLA ANTIGEN CLASS 1;

ALZHEIMER DISEASE; ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER; CONNECTIVE TISSUE DISEASE; CYTOKINE PRODUCTION; CYTOTOXICITY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DYSPHAGIA; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; LYMPHOCYTIC INFILTRATION; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE WEAKNESS; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POLYMYOSITIS; RESPIRATORY FAILURE; REVIEW; SKIN EDEMA; TOXOPLASMOSIS; VASCULAR DISEASE;

ADULT; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFANT; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 0142214436     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7 and 403-407.
2. Yunis J, Samaha F. Inclusion body myositis. Lab Invest 1971; 25: 240-8.
3. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991; 325: 1487-98.
4. Chérin P, Herson S. Myosites. In traité de Médecine, P Godeau, S Herson, JC Piette, eds. Flammarion, Paris 1996; 2184-91.
5. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255-86.
6. Metzger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1979; 48: 715-23.
7. Hilton-Jones D. Inflammatory muscle diseases. Curr Opin Neurol 2001; 14: 591-6.
8. Engel AG, R Hohfeld, Banker QB. Inflammatory myopathies. In: Myology, Engel AG, Banker BQ, eds. McGraw-Hill, New York 1994; 1335-83.
9. Marie I, Dominique S, Remy-Jardin et al. Pneumopathies interstitielles dans les polymyosites et dermatomyosites. Rev Med Int 2001; 22: 1083-96.
10. Cosnes A, Amaudric F, Gherardi R et al. Dematomyositis without muscle weakness. Long term follow-up of 12 patients without systemic corticoids. Arch Dermato 1995; 131: 1381-5.
11. Frazer DD, Frank JA, Dalakas M et al. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991, 18: 1693-8.
12. Love LA, Leff RL, Frase DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific antibodies define useful homogeneous patients groups. Medicine 1991; 70: 360-74.
13. Targoff I. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000; 12: 475-81.
14. Arahata K, Engel AG. Monoclonal antibody analysis of monoclonal cells in myopathies Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15.
15. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72.
16. Kissel JT, Mendell JR, Rammmohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-34.
17. Arahata K, Engel AG. Monoclonal antibody analysis of monoclonal cells in myopathies. IV. Cells-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988; 23: 168-73.
18. Dalakas MC. The molecular and cellular pathology of inflammatory muscle diseases. Curr opin pharmacol 2001; 3: 300-6.
19. Chérin P, Herson S, Crevon MC et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscles biopsies of myositis. Jrheumatol 1996; 23: 1135-42.
20. Mantegazza R, Andreetta F, Berasconi P et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis-restricted Va/b rearrangements may indicate an antigen-driven selection. J Clin Invest 1993; 91: 2880-6.
21. Benveniste O, Cherin P, Maisonobe T et al. Severe perturbations of the bood T cell repertoire in polymyositis, but not dermatomyositis patients. J immunol 2001; 167: 3521-9.
22. Hohfeld R, Engel Ag, Kunio I, Harper MC. Polymyositis mediated by T lymphocytes that express the g/d receptor. N Engl J Med 1991; 324: 877-81.
23. Nagaraju K, Raben N, Loeffler L et al. Conditional up-regulation of MHCl in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc natl Acad Sci USA 2000; 9209-14.
24. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G. Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berl) 2000; 99: 585-8
25. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000; 2: 216-24.
26. Pachman LM, Liotta-Davis Mr, Hong DK et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheumat 2000; 43: 2368-77.
27. Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol 1998; 2: 205-11.
28. Sigurgeirsson B, Lindel FB, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363-7.
29. Hill CL, Zhang Y, Sigurgeisson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population based study. Lancet 2001; 357: 96-100.
30. Tymms KE, Webb J. Dermatopolymyositis and other connective disease: a review of 105 cases. J Rheumatol 1985; 12; 1140-8.
31. Hausmanowa-Petrusewicz I, Kowalska-Olendzka E, Miller FW et al. Clinical, serological and immunogenetic features in polish patients with idiopathic inflammatory myopathies. Arthitis Rheuma 1997; 40: 1257-66.
32. Illa I, Nath A, Dalakas M. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies. Ann Neurol 1991; 29: 474-81.
33. Gherardi R, Chariot P, Authier FJ. Les atteintes musculaires au cours de l'infection par le VIH. Rev Neurol 1995; 151: 603-7.
34. Morgan OS, Rodgers-Johnson P, Mora CA, Char G. HTLV1 and polymyositis in Jamaica Lancet 1989; 2: 1184-7.
35. Halla JT, Fallahi S, Koopman WJ. Penicillamine induced myositis. Observations and unique features in two patients and review of the literature. Am J Med 1984; 77: 719-22.
36. Giordano N, Senesi M, Mattii G, Battisti et al. Polymyositis associated with Simvastatin. Lancet 1997, 349: 1600-1601.
37. Blume G, Petronsk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997; 120: 39-45.
38. Levine TD, Petronsk A. Inflammatory myopathy with cytochrome oxidase negative fibers: methotrexate treatment. Muscle nerve 1998; 21: 1724-8.
39. Layzer RB, Shearn MA, Satya-Murti S. Eosinophilic polymyositis. Ann Neurol 1977; 1: 65-78.
40. Urbano Marquez, Estruch R, Grau JM et al. Inflammatory myopathy associated with chroric graft versus host disease. Neurology 1986; 36: 1091-6.
41. Schmidley JW, Galloway P. Polymyositis following autologous bone marrow transplantation in Hodgkin's disease Neurology 1990; 40: 1003-4.
42. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420-8.
43. Benbassa T, J, Geffel D, Larholt K, Sukenik S, Morgenstein V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheumat 1985; 28: 249-55.
44. Grau JM, Miro O, Pedrol R et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996; 1921-6.
45. Maugars YM, Berthelot JM, Abbas AA et al. Long term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumathol 1996; 14: 263-76.
46. Gutierrez G, Dagnino R, Mintz G. Polymyositis/Dermatomyositis and pregnancy. Arthritis Rheumat 1984; 27: 291-4.
47. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28: 8-17.
48. Sivakumar K, Semino-Mora C, Dalakas CM. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Brain 1997; 120: 653-61.
49. Sivakumar K, Dalakas CM. Inclusion body myositis and myopathies. Curr Opin Neurol 1997; 10: 413-20.
50. Garlepp MJ, Laing B, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994; 98: 40-5.
51. Lotz B, Engel AG, Nishino H et al. Inclusion body myositis. Observation in 40 patients. Brain 1989; 112: 727-47.
52. Philipps BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study Muscle Nerve 2001; 1526-34.
53. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000; 55: 296-8.
54. Rugiero M, Koffman B, Dalakas MC. Association of inclusion body myositis with autoimmune diseases and autoantibody. Ann Neurol 1995; 38: 333-5.
55. Luciano CA, Dalakas MC. Inclusion body myositis. No evidence for a neurogenic component. Neurology 1997; 48: 29-33.
56. Figarella-Branger D, Pellissier JF, Bianco N, Devictor B, Toga M. Inflammatory and non-inflammatory inclusion body myositis. Characterization of the mononuclear cell and expression of the immunoreactive class I major histocompatibility complex product. Acta neuropathol 1990; 79: 528-36.
57. Askanas V, Engel WK, Alvarez RB. Enhanced detection of Congo-red positive amyloid deposits in muscle fibers of inclusion-body-myositis and brain of Alzheimer disease using fluorescenc technique. Neurology 1993; 43: 1265-7.
58. Askanas V, Engel WK, Alvarez RB, Glenner GG. Beta-amyloid protein immunoreactivity in muscle patients with inclusion body myositis. Lancet 1992; 339: 560-1.
59. Santorelli FM, Sciacco M, Tanji K et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis. Ann Neurol 1996; 39: 789-95.
60. Cupler EJ, Leon-Monzon M, Miller M, Semino Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV and HTLV1 infected patients. Brain 1996; 119: 1887-93.
61. Amemiya K, Granger RP, Dalakas MC. Cloral restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: studies in repeated muscle biopsies. Brain 2000; 123: 2030-9.
62. Askanas V, Engel WK. Inclusion-body myositis: newest concept of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 1-14.
63. Vattemi G, King Engel W, McFerrin J, Buxbaum JD, Pastorino L, Askanas V. Presence of BACE1 and BACE2 in muscle fibers of patients with sporadic inclusion-body myositis. Lancet 2001; 358: 1962-4.
64. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculo-pharyngeal muscular dystrophy. Neurosci Lett 1991; 130: 73-6.
65. Lodi R, Taylor DJ, Tabrizi SJ et al. Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion myositis assessed by 31 P magnetic resonance spectroscopy. Brain 1998; 121: 2119-26.
66. Baron P, Galimberti D, Meda L et al. Production of IL6 by human myoblasts stimulated with Ab. Relevance in the pathogenesis of IBM. Neurology 2001; 57: 1561-5.
67. Pruitt JN, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996; 39: 139-43.
68. Eymard B, Brouet JC, Collin H, Bussel A, Fardeau M. Late onset myopathy associated with monoclonal gammopathy. Neuromusc Disord 1993; 3: 557-60.
69. Gherardi RK, Coquet M, Chérin P et al. Macrophagic myofascitis: an emerging entity. Lancet 1998; 352: 347-51.